BiomX Investor Relations Material
Latest events
Q1 2025
BiomX
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BiomX Inc
Access all reports
BiomX Inc. is a clinical-stage biotechnology company specializing in the development of both natural and engineered phage therapies. These therapies are designed to target and eliminate specific harmful bacteria, particularly those involved in chronic diseases. The company's key focus areas include conditions like cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX utilizes its proprietary phage technology to discover and validate bacterial targets, subsequently customizing phage compositions to combat these targets effectively. The company is headquartered in Ness Ziona, Israel, and its shares are listed on the NYSE.
Key slides for BiomX Inc

Q4 2024 & Study Result
BiomX Inc

Q4 2024 & Study Result
BiomX Inc
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
PHGE
Country
🇺🇸 United States